CHI Report – Innovation in Hepatitis C Treatment – Page – 10
i United States Centers for Disease Control, Department of Viral Hepatitis. Viral Hepatitis Surveillance, United States, 2011 (accessed online at: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/PDFs/2011HepSurveillanceRpt.pdf)
ii Mahajan R, et al., “Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality Among Persons in Care with Hepatitis C Virus Infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010,” Clinical Infectious Diseases, 2014.
iii Product label of PEGASYS, peginterferon alfa-2a (http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm094462.pdf, accessed on 7/3/2014)
iv Tice J, et al., “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the treatment of Chronic Hepatitis C infection, A Technology Assessment,” California Technology Assessment Forum, 2014.
v Epidemiological modeling by the Center for Disease Analysis (unpublished).
vi Nainan OV, et al., “Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States,” Gastroenterology, 2006.
vii Chak E, et al., “Hepatitis C Virus Infection in USA: An Estimate of True Prevalence,” Liver International, February 2011.
viii Koh HK, et al., “Hepatitis C Virus Infection in Young Persons Who Inject Drugs,” Technical Consultation, 2013 (http://aids.gov/pdf/hcv-and-young-pwid-consultation-report.pdf, accessed on 7/3/2014)
ix Armstrong GL, et al., “The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002,” Annals of Internal Medicine, 2006.
x Pyenson B,et al., Healthcare reform and hepatitis C: A convergence of risk and opportunity, Milliman Associates, 2013.
xi US CDC, Hepatitis C Factsheet (http://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf, accessed on 7/3/2014)
xii Rein DB, et al., “The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings,” Annals of Internal Medicine, 2012.
xiii American Liver Foundation website (http://hepc.liverfoundation.org/, accessed on 7/3/2014)
xiv Transplant living (http://www.transplantliving.org/before-the-transplant/financing-a-transplant/the-costs/, accessed on 7/14/2014)
xv Edlin BR. “Perspective: Test and Treat This Silent Killer.” Nature, 2011.
xvi Ly KN, et al., “The Increasing Burden of Mortality from Viral Hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, 2012.
xvii U.S. CDC HIV and Viral Hepatitis Fact Sheet (http://www.cdc.gov/hepatitis/Populations/PDFs/HIVandHep-FactSheet.pdf, accessed on 7/3/2014)
xviii Strader DB, et al., “A Brief History of the Treatement of Viral Hepatitis C,” Clinical Liver Disease, 2012
xix Bruno S, et al., “Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus-Induced Cirrhosis. A 12-year prospective follow-up study,” Hepatology, 2010.
xx van der Meer AJ, et al., “Association Between Sustained Virological Response and All-Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis,” Journal of the American Medical Association, 2012.
xxi LaFleur J, et al., “High Rates of Early Treatment Discontinuation in Hepatitis C-Infected US Veterans,” BMC Res Notes, 2014.
xxii Brennan and Shrank, “New Expensive Treatments for Hepatitis C Infection,” Journal of the American Medical Association, 2014.
xxiii Razavi H, et al., “The Present and Future Disease Burden of Hepatitis C Virus (HCV) Infection with Today’s Treatment Paradigm,” Journal of Viral Hepatology, 2014.
xxiv Heathcote EJ, et al. “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis,” New England Journal of Medicine, 2000.